Therapy Areas: Cardiovascular
Frail Patients with NVAF Experience Fewer Strokes, Systemic Emboli When Treated with Xarelto Compared to Warfarin
30 May 2018 - - Titusville, New Jersey-based Janssen Pharmaceutical Companies, a segment of US-based global healthcare company Johnson and Johnson (NYSE: JNJ), has released data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced reduced risk of stroke and systemic embolism by 32% and ischemic stroke alone by 31% when treated with Xarelto over a two-year period compared to warfarin, with no increased rate of major bleeding, the company said.
In the study, researchers used US Truven MarketScan claims data and identified 10,754 frail patients with NVAF taking Xarelto, apixaban, dabigatran, or warfarin.
Frailty was determined using the Johns Hopkins Claims-based Frailty Indicator scoring algorithm. The primary efficacy outcome was stroke (ischemic or hemorrhagic) or systemic embolism. Major bleeding was the primary safety outcome.
Xarelto (rivaroxaban) is an oral factor Xa inhibitor used in the treatment of or prevention of blood clots in people with predisposing medical conditions or surgical history associated with high risk for thrombosis.
The Janssen Pharmaceutical Companies of Johnson and Johnson work to find new and better ways to prevent, intercept, treat, and cure disease. The pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular, and metabolic diseases.
Login
Username:

Password: